Curasight A/S

Equities

CURAS

DK0061295797

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
11.4 ^DKK	+0.88%		-2.56%	-35.77%

Jun. 12	Curasight A/S Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer	CI
May. 23	Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BioStock: Curasight targets prostate cancer with theranostic approach

January 07, 2022 at 02:36 am EST

Danish biotech company Curasight is developing its theranostic platform to target and assess the aggressiveness of cancer tumours. The technology recently showed promising results in an investigator-initiated phase II trial in prostate cancer. In this article, BioStock takes a closer look at the prostate cancer diagnostics landscape to gain insight into how the company intends to position its product candidate uTRACE.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/curasight-targets-prostate-cancer-with-theranostic-approach/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/curasight/r/biostock--curasight-targets-prostate-cancer-with-theranostic-approach,c3481748

Latest news about Curasight A/S

Curasight A/S Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer	Jun. 12	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	Apr. 16	CI
Curasight A/S Announces Board Changes	Apr. 12	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	Feb. 13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	Dec. 22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	Dec. 18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	23-10-18	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	23-09-14	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	23-06-29	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	23-06-07	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	23-05-11	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	23-05-01	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors	22-10-13	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer	22-06-30	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI

Chart Curasight A/S

Duration

Period

More charts

Company Profile

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURASIGHT A/S	-35.77%	33.08M
MODERNA, INC.	+21.27%	47.96B
IQVIA HOLDINGS INC.	+1.48%	42.45B
LONZA GROUP AG	+43.85%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.94%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.19%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.58%	14.56B
MEDPACE HOLDINGS, INC.	+44.33%	14.14B
BIO-TECHNE CORPORATION	+2.94%	12.58B

Other Biotechnology & Medical Research